Publications

Nature communications

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

09-09-2020

Key

bioRxiv

Human Prostate Cancer-Associated Macrophage Subtypes and Prognostic Potential Revealed by Single-cell Transcriptomics

20-06-2020

Key

The Journal of clinical investigation

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

19-11-2024

European urology oncology

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.

01-10-2024

The Journal of clinical investigation

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.

13-08-2024

Clinical genitourinary cancer

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.

01-04-2024

NPJ systems biology and applications

Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.

21-02-2024

Journal of clinical pharmacology

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

01-02-2024

Cancers

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.

10-01-2024

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.

31-12-2023

Pharmaceutical research

Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.

01-12-2023

European urology

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

01-11-2023

Cancer research communications

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

01-08-2023

Cancers

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

06-06-2023

Cancers

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options.

29-05-2023

Prostate cancer and prostatic diseases

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.

01-03-2023

European urology open science

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.

01-03-2023

Urologic oncology

Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.

01-02-2023

European urology open science

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl).

01-02-2023

European urology oncology

Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.

01-02-2023

Clinica chimica acta; international journal of clinical chemistry

Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.

15-01-2023

Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022

Endocrinology

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

11-10-2022

Clinical chemistry and laboratory medicine

Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.

27-09-2022

Advances in experimental medicine and biology

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

16-09-2022

Cancer discovery

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

02-09-2022

Drugs - real world outcomes

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.

01-06-2022

Cancer chemotherapy and pharmacology

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

01-06-2022

Clinical epigenetics

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

04-05-2022

Clinical genitourinary cancer

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.

01-04-2022

Clinical genitourinary cancer

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.

01-02-2022

Prostate cancer and prostatic diseases

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.

01-02-2022

Cell reports

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

14-12-2021

Journal of palliative medicine

High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.

01-12-2021

Nature communications

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.

04-11-2021

Trials

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.

04-11-2021

Clinica chimica acta; international journal of clinical chemistry

Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications.

01-10-2021

Molecular cancer research : MCR

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

01-10-2021

Nature cell biology

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

01-09-2021

Prostate cancer and prostatic diseases

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.

01-09-2021

Cancers

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.

27-08-2021

Cancer reports (Hoboken, N.J.)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.

01-08-2021

European urology oncology

Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.

01-08-2021

Molecular oncology

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

01-07-2021

Scientific reports

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

01-07-2021

European urology focus

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.

01-07-2021

Cancer chemotherapy and pharmacology

Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.

01-06-2021

Genome biology

Functional mapping of androgen receptor enhancer activity.

11-05-2021

Future oncology (London, England)

The intravenous to oral switch of taxanes: strategies and current clinical developments.

01-04-2021

Nature communications

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.

15-01-2021